• Most Popular
  • Most Shared

Access Pharmaceuticals stock undervalued-magazine

Thu Feb 1, 2007 9:42pm EST

Stocks

   

NEW YORK, Feb 1 (Reuters) - Access Pharmaceuticals (ACCP.OB), a tiny biotechnology company, is undervalued based on the market potential of its cancer products, fund managers told BusinessWeek magazine in its Feb. 12 issue.

Access, which is traded over-the-counter, has one product, MuGard, approved by the U.S. Food and Drug Administration and another one in mid-stage clinical trials, the article stated.

MuGard is a treatment for oral mucositis, a side effect of radiation therapy that affects some 40 percent of a $1.5 billion market. The other drug, ProLindac, has various cancer applications and is a "potential blockbuster," H4 Capital hedge fund investor Kevin Raidy told the magazine.

Raidy said MuGard alone is worth more than the stock's current value, according to BusinessWeek.

Access closed at $3 on Thursday, up 5 cents.



More from Reuters

Photo

Jobless claims up, but leading indicators improve

WASHINGTON (Reuters) - The number of U.S. workers filing new applications for jobless insurance unexpectedly rose last week, but a gauge of future economic activity increased for the eighth month in a row, pointing to a slow economic recovery where employment looms as the dominant concern.

A girl sits on her father's shoulders in front of a globe with an interactive display during an Earth Hour ceremony at the townhall square in central Copenhagen December 16, 2009. Credit: REUTERS/Christian Charisius

U.N. talks at "critical juncture"

Climate talks were given a second chance after the U.S. backed a $100 billion global fund to support poor countries. What else will it take to hammer out a deal?  Full Article 

Bernd Debusmann

Burning borrowed money

The Pentagon burns through $5 million in borrowed money every hour in Afghanistan and the amount is expected to more than double once additional troops are deployed.   Commentary